PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808942
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808942
Lab Automation In Genomics Market size was valued at US$ 2,350.43 Million in 2024, expanding at a CAGR of 16.10% from 2025 to 2032.
Lab automation in genomics pertains to the implementation of sophisticated robotic systems, software, and integrated instruments designed to streamline and enhance workflows associated with genetic analysis. These systems are vital in improving throughput, accuracy, and reproducibility across a range of genomic applications, including DNA/RNA extraction, PCR setup, library preparation for sequencing, and data analysis. The process involves substituting or reducing manual, repetitive laboratory tasks with automated solutions, thereby boosting efficiency, accuracy, reproducibility, and throughput in genomics laboratories. Lab automation has become indispensable in contemporary genomics, especially as the demand for personalized medicine, high-throughput sequencing, and extensive genomic studies continues to rise.
Lab Automation In Genomics Market- Market Dynamics
High Demand for High-Throughput Genomic Analysis and Rising Investment in Genomics Research is anticipated to drive the growth of market
As the demand for genetic testing and sequencing rises, particularly in fields like personalized medicine, drug discovery, and clinical diagnostics, laboratories face increasing pressure to process a high volume of samples swiftly and accurately. Automation in laboratories facilitates quicker turnaround times, enhances precision, and minimizes human error. In 2023, the National Human Genome Research Institute (NHGRI) in the United States allocated over USD600 million for genomics research. Their budget request for that year amounted to USD 629.2 million, as reported by NHGRI. Additionally, the surge in Genomics and Personalized Medicine may present growth opportunities for the market. Nevertheless, issues related to integration and compatibility could hinder market expansion.
Lab Automation In Genomics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.10% over the forecast period (2025-2032)
Based on product type segmentation, Automated Liquid Handlers was predicted to show maximum market share in the year 2024
Based on End-User segmentation, Academic Institutions was the leading End-User in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Lab Automation In Genomics Market is segmented on the basis of Product Type, Process, Technology, End-User, and Region.
The market is segmented into three categories according to product type: Automated Liquid Handlers, Automated Plate Handlers, Robotic Arms, Automated Storage and Retrieval Systems, and Other Types. Automated Liquid Handlers lead the market growth, owing to their exceptional precision, efficiency, and capability to handle large sample volumes with minimal human involvement. These systems greatly improve throughput and reproducibility in genomic workflows, including DNA/RNA extraction, PCR setup, and next-generation sequencing (NGS) library preparation. Their extensive adoption is fueled by the increasing demand for streamlined operations in research laboratories, clinical diagnostics, and pharmaceutical development.
The market is categorized into two types based on Process: Continuous Automation System and Modular Automation System. Continuous automation systems are designed to integrate smoothly into comprehensive workflows, facilitating continuous sample processing and high-throughput genomic applications, including next-generation sequencing (NGS) and PCR analysis. Conversely, modular automation systems provide flexibility and scalability, enabling laboratories to tailor workflows according to particular genomic processes. The capability of automated liquid handlers to ensure accuracy, consistency, and efficiency across both system types renders them essential for the progress of genomic research and diagnostics.
The market is categorized into two segments based on Technology: Microarray Technology, Next Generation Sequencing Technology, Capillary Electrophoresis Technology, and Sanger Sequencing Technology. Their capability to accurately manage microliter to nanoliter volumes greatly improves sample preparation efficiency and minimizes the likelihood of human error. In NGS, they optimize intricate workflows such as library preparation and reagent dispensing. For Microarray and Capillary Electrophoresis, automated liquid handlers guarantee reproducibility and precision in hybridization and separation processes. In Sanger Sequencing, these systems enable high-throughput sample setup, leading to quicker turnaround times. Their versatility across various genomic technologies establishes them as a crucial factor in enhancing efficiency, scalability, and data quality in contemporary genomics laboratories.
The market is categorized into two segments based on End-User: Academic Institutions, Pharmaceutical Companies, Biotechnology Firms, and Contract Research Organizations. Academic Institutions are leading the growth of the market, propelled by rising investments in life science research, government-sponsored genome initiatives, and partnerships with biotech companies. These institutions are pioneers in the adoption of cutting-edge technologies such as Automated Liquid Handlers, Next Generation Sequencing (NGS), and Microarray Platforms to expedite genomic discoveries. With a strong emphasis on research and innovation, academic laboratories necessitate high-throughput, precise, and reproducible systems rendering lab automation crucial for scaling complex genomic studies. The increasing emphasis on personalized medicine, molecular biology, and genetic diagnostics further drives the demand for automated solutions in academic research settings.
Lab Automation In Genomics Market- Geographical Insights
North America leads the market, driven by the Growing Demand for Personalized Medicine. This region enjoys a robust healthcare infrastructure, substantial investments in genomics research, and the early implementation of cutting-edge lab automation technologies. Strong governmental backing, the presence of prominent biotech companies, and the rising use of genomics in diagnostics and targeted therapies further enhance market expansion throughout the region. The approval of 12 personalized medicines accounts for roughly 34 percent of all newly sanctioned therapeutic molecular entities. Personalized medicines have consistently represented at least a quarter of new drug approvals over the past eight years. In 2023, the U.S. Food and Drug Administration (FDA) has sanctioned 55 new drugs, a number that aligns with the approvals seen in the previous five years. Europe ranks as the second largest region for market growth, attributed to increasing governmental support for genomic medicine and precision health.
The market for lab automation in genomics is extremely competitive, with leading companies concentrating on technological innovations, strategic partnerships, and product development to enhance their market presence. Prominent firms are leading the way by providing a diverse array of automated solutions, which include liquid handling systems, robotic workstations, and integrated platforms designed for genomic workflows. These companies compete on the basis of precision, scalability, throughput, and user-friendly software interfaces. Moreover, new entrants and startups are making their way into the market with modular and cost-effective automation tools specifically designed for academic and research institutions, thereby intensifying the competitive environment. Ongoing research and development initiatives, along with collaborations with genomics laboratories and academic institutions, continue to influence the dynamics of this rapidly evolving market.
Thermo Fisher Scientific Inc. Thermo Fisher, recognized as the global leader in scientific services, has currently unveiled the Thermo Scientific Vulcan Automated Lab, an innovative solution aimed at ushering in a new phase of process development and control within the semiconductor manufacturing sector. This fully integrated system is intended to boost productivity, improve yield, and lower operating expenses for semiconductor producers.